Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?

Johnson & Johnson beat Q1 2026 estimates, raised full-year guidance conservatively, and reported strong sales from Darzalex ($4.0B) and Tremfya ($1.6B). However, Stelara sales fell sharply to $656M from $1.6B in Q1 2025 after patent expiry and generic competition, tempering investor reaction and leaving the stock slightly lower. The company also highlighted 64 consecutive years of dividend increases.

Analysis

The market is treating this as a quality miss rather than a fundamental break: the company is still compounding, but the stock has likely been priced for near-flawless execution after a strong multi-quarter run. The real issue is not the earnings beat; it’s the visibility gap created by a sharp patent-driven revenue air pocket in one franchise that makes the near-term growth algorithm look less linear. That kind of mix shift tends to compress multiple expansion even when headline EPS is fine, because investors start marking the business on replacement growth rather than reported growth.

Second-order, the patent cliff is a competitive signal for the broader immunology/autoimmune space. As share migrates, the beneficiaries are not just direct biosimilar entrants but also adjacent branded incumbents with cleaner exclusivity runways, since payers will use the reference-price reset to demand tougher contracting across the category. That can create a temporary headwind for other large-cap pharma names with similar exposure to specialty pricing pressure, even if their own fundamentals are intact.

The contrarian takeaway is that the stock’s muted reaction may be overdone if investors are extrapolating the patent erosion too aggressively. The pipeline and capital return profile matter more in a year where large-cap defensives can re-rate on durability, especially if macro growth slows and rate volatility stays elevated. The key catalyst over the next 1-3 months is whether management can demonstrate that newer drugs are accelerating fast enough to offset the loss rather than merely stabilize it; if they can, the market should re-focus on cash flow resilience and dividend support.

For now, the setup favors patience over chase: the stock likely needs either another pullback or a fresh catalyst to re-establish upside momentum. If that catalyst fails to emerge, the shares can drift as investors wait for the next quarterly proof point. But absent a broader market risk-on move, the downside here looks more like multiple compression than a fundamental derating event.

Key Decisions for Investors

• Hold off on adding to JNJ for 2-4 weeks; wait for post-earnings drift to fade or for a clearer read on whether new-product growth can offset patent erosion. Risk/reward improves materially if the stock revisits a lower multiple before the next catalyst.
• Use JNJ as a defensive pair leg: long JNJ / short a higher-duration, higher-multiple healthcare name with less cash return support. The thesis is relative multiple compression in the less visible name if the market rotates toward balance-sheet quality and dividend durability.
• If already long JNJ, consider selling covered calls 30-60 days out to monetize the likely consolidation phase. This turns a low-volatility stall into income while limiting regret if the stock remains range-bound.
• Watch biosimilar-exposed healthcare peers over the next 1-2 quarters; a short basket of names with similar exclusivity cliffs could outperform if contracting pressure widens. The setup is best expressed as a relative-value trade rather than an outright sector short.
• Do not short JNJ outright here; the downside is likely capped by dividend/supportive flows unless the next print shows acceleration failure. Risk/reward is poor for an absolute bearish bet, but attractive for premium-selling or pair structures.